FindTrial
Sign In

INO-9012

BIOLOGICAL6 trials

Sponsors

Inovio Pharmaceuticals, Steven Deeks, Geneos Therapeutics, Abramson Cancer Center at Penn Medicine

Conditions

BRCA1/2 MutationBreast CancerColoRectal CancerEsophageal CancerGastric CancerGlioblastomaHCCHIV-1-infection

Phase 1

hTERT Immunotherapy Alone or in Combination With IL-12 DNA Followed by Electroporation in Adults With Solid Tumors at High Risk of Relapse
CompletedNCT02960594
Inovio PharmaceuticalsBreast Cancer, ColoRectal Cancer, Esophageal Cancer +6
Start: 2014-12-31End: 2018-11-09Updated: 2018-11-19
INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)
Active, not recruitingNCT03491683
Inovio PharmaceuticalsGlioblastoma
Start: 2018-05-31End: 2026-12-31Updated: 2026-03-19
INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma
CompletedNCT03502785
Inovio PharmaceuticalsUrothelial Carcinoma
Start: 2018-05-24End: 2025-05-09Updated: 2025-07-10
Therapeutic Vaccination in Treated HIV Disease
CompletedNCT03606213
Steven DeeksHIV-1-infection
Start: 2018-08-01End: 2021-05-17Updated: 2023-05-31
GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects with Advanced HCC
Active, not recruitingNCT04251117
Geneos TherapeuticsHCC
Start: 2020-03-01End: 2028-11-29Updated: 2025-01-31
INO 5401 Vaccination in BRCA1/2 Mutation Carriers
Active, not recruitingNCT04367675
Abramson Cancer Center at Penn MedicineBRCA1/2 Mutation
Start: 2021-04-20End: 2027-03-01Target: 44Updated: 2026-02-23

Related Papers

Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals with <i>BRCA1/2</i> mutations.
Journal of Clinical Oncology2025-05-281 citations
Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial.
2024-04-07135 citations
Abstract 976: Detection of circulating tumor DNA predicts survival in advanced HCC patients treated with personalized therapeutic DNA cancer vaccine in combination with immune checkpoint blockade
Cancer Research2024-03-22
Effect of personalized immunization with GNOS-PV02 of patients with hepatocellular carcinoma on TCR clonal expansion, tumor infiltration, and vaccine-specific reactivity.
Journal of Clinical Oncology2023-06-01
Tracking MRD and neoantigen targets using a tumor-informed liquid biopsy platform in HCC patients treated with personalized cancer vaccine and pembrolizumab.
Journal of Clinical Oncology2023-06-01
692 Circulating tumor DNA analysis of advanced hepatocellular cancer (HCC) patients treated with neoantigen targeted personalized cancer DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab)
Regular and Young Investigator Award Abstracts2022-11-015 citations
693 Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab as second-line (2L) treatment for advanced hepatocellular carcinoma (HCC)
Regular and Young Investigator Award Abstracts2022-11-011 citations
691 Immune pressure in an advanced hepatocellular cancer patient following treatment with personalized neoantigen DNA vaccine (GNOS-PV02) in combination with plasmid IL-12 (pIL12) and anti-PD1 (pembrolizumab)
Regular and Young Investigator Award Abstracts2022-11-011 citations
Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma.
Journal of Clinical Oncology2022-06-0123 citations
453 Personalized DNA neoantigen vaccine (GNOS-PV02) in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma
Regular and Young Investigator Award Abstracts2021-11-019 citations
Personalized DNA neoantigen vaccine in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma.
Journal of Clinical Oncology2021-05-208 citations
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies
Targeted Oncology2021-05-0329 citations
LTBK-01. INO-5401 AND INO-9012 DELIVERED INTRAMUSCULARLY (IM) WITH ELECTROPORATION (EP) IN COMBINATION WITH CEMIPLIMAB (REGN2810) IN NEWLY DIAGNOSED GLIOBLASTOMA
Neuro-Oncology2020-11-017 citations
INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results.
Journal of Clinical Oncology2020-05-2020 citations
P858 An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab in subjects with newly-diagnosed glioblastoma (GBM)
Poster presentations2020-04-013 citations
Abstract CT114: INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab (REGN2810) in newly-diagnosed glioblastoma (GBM) (NCT03491683)
Cancer Research2019-07-017 citations
Abstract CT114: INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab (REGN2810) in newly-diagnosed glioblastoma (GBM) (NCT03491683)
Clinical Trials2019-07-013 citations
Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma
Cancer Research2019-07-011 citations
Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma
Clinical Trials2019-07-01